Drexel Distribution INC

Drexel Distribution INC was paid $1.68M by Medicaid between Mar 2022 and Nov 2023, across 11 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 39% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#50 of 116

Median peer was paid$618K

This provider vs. median2.7×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2022	38,767	$1.14M
2023	17,673	$545K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	39%	12,815	8,761	$653K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	28%	18,293	12,175	$468K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	13%	12,537	8,666	$216K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	11%	2,778	2,335	$192K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	4.8%	6,228	4,077	$81K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.9%	1,182	1,120	$31K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	1.5%	1,108	931	$26K
87634		<1%	1,073	900	$11K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	107	94	$2K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	23	21	$672.65
99001		<1%	296	295	$4.26

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialZORMATI, BEDIS (OWNER)